Focus on flunarizine

A calcium antagonist for the treatment of neurologic disorders

Research output: Contribution to journalReview article

Abstract

Flunarizine is a unique calcium antagonist that inhibits excess calcium influx into cells. Although the pharmacokinetics of the drug have not been fully characterized, flunarizine appears to be extensively metabolized. The drug has a large volume of distribution (43.2 l/kg) and a long elimination half-life (19 days). The effectiveness of flunarizine is currently being investigated in the prophylaxis of migraine headache in both children and adults, as add-on therapy in refractory epilepsy in patients with partial complex seizures who are receiving combinations of other anticonvulsants, in the treatment of vertigo primarily due to peripheral causes, and in alternating hemiplegia in children. Flunarizine is generally well tolerated and no major organ system toxicity has been reported to date. The most common side effect seen is drowsiness, occurring in about 7% of patients.

Original languageEnglish
Pages (from-to)705-710
Number of pages6
JournalHospital Formulary
Volume25
Issue number7
StatePublished - 1990

Fingerprint

Flunarizine
Nervous System Diseases
Calcium
Sleep Stages
Vertigo
Therapeutics
Migraine Disorders
Pharmaceutical Preparations
Anticonvulsants
Half-Life
Epilepsy
Seizures
Pharmacokinetics

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Focus on flunarizine : A calcium antagonist for the treatment of neurologic disorders. / Hilleman, Daniel E.; Mohiuddin, Syed M.

In: Hospital Formulary, Vol. 25, No. 7, 1990, p. 705-710.

Research output: Contribution to journalReview article

@article{04bc1a34fa4a4fb9ba28247bd31aa0b4,
title = "Focus on flunarizine: A calcium antagonist for the treatment of neurologic disorders",
abstract = "Flunarizine is a unique calcium antagonist that inhibits excess calcium influx into cells. Although the pharmacokinetics of the drug have not been fully characterized, flunarizine appears to be extensively metabolized. The drug has a large volume of distribution (43.2 l/kg) and a long elimination half-life (19 days). The effectiveness of flunarizine is currently being investigated in the prophylaxis of migraine headache in both children and adults, as add-on therapy in refractory epilepsy in patients with partial complex seizures who are receiving combinations of other anticonvulsants, in the treatment of vertigo primarily due to peripheral causes, and in alternating hemiplegia in children. Flunarizine is generally well tolerated and no major organ system toxicity has been reported to date. The most common side effect seen is drowsiness, occurring in about 7{\%} of patients.",
author = "Hilleman, {Daniel E.} and Mohiuddin, {Syed M.}",
year = "1990",
language = "English",
volume = "25",
pages = "705--710",
journal = "Hospital Formulary",
issn = "0098-6909",
publisher = "Advanstar Communications",
number = "7",

}

TY - JOUR

T1 - Focus on flunarizine

T2 - A calcium antagonist for the treatment of neurologic disorders

AU - Hilleman, Daniel E.

AU - Mohiuddin, Syed M.

PY - 1990

Y1 - 1990

N2 - Flunarizine is a unique calcium antagonist that inhibits excess calcium influx into cells. Although the pharmacokinetics of the drug have not been fully characterized, flunarizine appears to be extensively metabolized. The drug has a large volume of distribution (43.2 l/kg) and a long elimination half-life (19 days). The effectiveness of flunarizine is currently being investigated in the prophylaxis of migraine headache in both children and adults, as add-on therapy in refractory epilepsy in patients with partial complex seizures who are receiving combinations of other anticonvulsants, in the treatment of vertigo primarily due to peripheral causes, and in alternating hemiplegia in children. Flunarizine is generally well tolerated and no major organ system toxicity has been reported to date. The most common side effect seen is drowsiness, occurring in about 7% of patients.

AB - Flunarizine is a unique calcium antagonist that inhibits excess calcium influx into cells. Although the pharmacokinetics of the drug have not been fully characterized, flunarizine appears to be extensively metabolized. The drug has a large volume of distribution (43.2 l/kg) and a long elimination half-life (19 days). The effectiveness of flunarizine is currently being investigated in the prophylaxis of migraine headache in both children and adults, as add-on therapy in refractory epilepsy in patients with partial complex seizures who are receiving combinations of other anticonvulsants, in the treatment of vertigo primarily due to peripheral causes, and in alternating hemiplegia in children. Flunarizine is generally well tolerated and no major organ system toxicity has been reported to date. The most common side effect seen is drowsiness, occurring in about 7% of patients.

UR - http://www.scopus.com/inward/record.url?scp=0025088243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025088243&partnerID=8YFLogxK

M3 - Review article

VL - 25

SP - 705

EP - 710

JO - Hospital Formulary

JF - Hospital Formulary

SN - 0098-6909

IS - 7

ER -